# Crohn Disease

Crohn disease requires objective confirmation, phenotype-based risk assessment, steroid-sparing treatment, and longitudinal monitoring beyond symptoms. Ileocolonoscopy with biopsy establishes diagnosis and extent; biomarkers and cross-sectional imaging help detect ongoing inflammation, complications, and discordance between symptoms and disease activity.

**Clinical question:** How should physicians confirm, risk-stratify, treat, and objectively monitor Crohn disease while preventing avoidable complications?

Updated: 2026-08-21T01:35:12.709511+00:00

## What matters in practice
- At presentation, ileocolonoscopy with biopsy is the first-line diagnostic test because it defines extent and provides histology needed to distinguish Crohn disease from infectious, drug-induced, and ischemic mimics. [3]
- Symptoms and serum CRP can underestimate active mucosal disease; fecal calprotectin is useful for triage and monitoring but is less reliable in isolated small-bowel disease. [15][16]
- Systemic corticosteroids are appropriate induction therapy for moderate-to-severe uncomplicated luminal disease but should not become maintenance therapy; extensive disease or poor prognostic features support early biologic consideration. [1]
- 5-aminosalicylates have little to no role in Crohn disease management, including postoperative maintenance. [3]
- Persistent symptoms require confirmation of inflammatory activity before escalation; conversely, objective inflammation despite clinical improvement warrants reassessment because clinical indices and CRP do not reliably identify endoscopic remission. [16]

## Confirm disease and define inflammatory burden

Establish anatomy, histology, and complications before committing to long-term immunosuppression.

Use ileocolonoscopy with segmental biopsy as the first-line test at index presentation. It assesses colonic and terminal ileal extent and supplies histology, which remains particularly important for separating Crohn disease from infection, medication-related injury, ischemia, and other mimics before medical therapy is initiated. [3]

Pair endoscopy with cross-sectional imaging when small-bowel extent, transmural inflammation, penetrating disease, obstruction, or extraluminal complications are suspected. In an uncertain presentation, fecal calprotectin can help determine whether ileocolonoscopy and imaging are warranted. [14] Capsule endoscopy is an adjunct for patients with high clinical suspicion of small-bowel Crohn disease; deep enteroscopy is not routine but can provide tissue when small-bowel sampling is required. [2]

Obtain a baseline CBC and inflammatory markers, recognizing their limitations. Anemia and thrombocytosis are common hematologic abnormalities; CRP and ESR are standard acute-phase surrogates, but normal values do not exclude active disease in an individual patient. [15][22] Screen for iron, 25-hydroxyvitamin D, folate, and vitamin B12 deficiency. [14]
- Use fecal calprotectin or lactoferrin as adjunctive evidence of intestinal inflammation; low CRP and/or low calprotectin had a 99% negative predictive value for IBS in one meta-analysis summarized by ECCO. [15]
- Interpret a low fecal calprotectin cautiously in isolated ileal disease, where fecal markers may be less sensitive and correlate imperfectly with transmural inflammation. [15][16]
- When diagnosis remains uncertain after standard evaluation, capsule endoscopy may add diagnostic information in selected patients; obtain tissue by enteroscopy only when it will change diagnosis or management. [2][18]

*Objective assessment tools and their principal clinical use in Crohn disease. [2][3][15][16]*

| Tool | Best use | Interpretive limitation |
| --- | --- | --- |
| Ileocolonoscopy with biopsy | Initial confirmation, extent assessment, histologic diagnosis, and mucosal reassessment. [3][16] | Does not fully characterize proximal small bowel or transmural/extraluminal disease. [14][16] |
| Cross-sectional imaging | Assessment of small-bowel involvement and complications beyond the mucosa. [14] | Does not replace biopsy-based diagnostic evaluation at presentation. [3] |
| Fecal calprotectin | Triage for further investigation and serial assessment of inflammatory activity. [14][15] | May be falsely reassuring in isolated small-bowel disease; individual thresholds are not uniform. [15][16] |
| CRP and ESR | Serial adjuncts to assess inflammatory activity. [15] | May not correlate with an individual patient's clinical or endoscopic disease activity. [16][22] |

## Use induction therapy to gain control, then transition to durable steroid-sparing management

Treatment selection should reflect inflammatory severity, extent, behavior, complications, and prior treatment exposure.

For moderate-to-severe uncomplicated luminal Crohn disease, systemic corticosteroids are recommended for initial induction. Patients with extensive disease or poor prognostic features should be considered for earlier biologic therapy rather than repeated conventional-treatment cycles. [1] Corticosteroids should be viewed as induction agents, not a strategy for durable disease control.

For mild-to-moderate disease, available evidence summaries describe budesonide, sulfasalazine, and dietary modifications as induction options, with treatment choice influenced by disease location and severity. [14] Do not extrapolate ulcerative colitis practice to Crohn disease: 5-aminosalicylates have little to no role in Crohn disease management, including postoperative maintenance. [3]

For steroid-dependent or steroid-resistant disease, older ECCO guidance summarized in a quality review identifies azathioprine or mercaptopurine as first-line steroid-sparing options and methotrexate when purine analogues are ineffective or not tolerated; biologic therapy is appropriate when conventional therapy fails, is not tolerated, or disease is moderate to severe. [2][19] Contemporary agent selection requires current guideline and labeling review because the supplied evidence does not provide U.S. dosing, safety screening, or comparative positioning among biologics and small molecules.
- Avoid repeated corticosteroid exposure as a substitute for maintenance therapy; recurrent steroid requirement should trigger reassessment of disease activity, complications, adherence, and a steroid-sparing plan. [1][2]
- Before immunomodulator or biologic treatment, obtain vaccination history and update vaccinations. Live vaccines should be administered at least 4 weeks before immunosuppression or at least 3 months after stopping it, and not during immunosuppressive therapy. [1]
- For adalimumab, adding an immunomodulator did not improve pooled induction or maintenance remission versus monotherapy, but was associated with lower odds of anti-adalimumab antibody development; infection tradeoffs remain relevant. [20]

### Treat symptoms and objective inflammation as separate targets

Clinical response and remission definitions are useful trial constructs but do not establish mucosal control. In Crohn disease, clinical remission is commonly defined as a Crohn's Disease Activity Index below 150, whereas endoscopic response is a greater than 50% decrease in the Simplified Endoscopic Score for Crohn's Disease; these outcomes should not be assumed to coincide. [5]
- Do not escalate solely for nonspecific symptoms without objective evidence of inflammatory activity; pain and bowel dysfunction may have noninflammatory contributors. [22]
- Do not accept symptom control alone as proof of remission when biomarkers, imaging, or endoscopy suggest ongoing disease. Clinical indices and CRP were not reliable for identifying endoscopic remission in an anti-TNF-treated cohort. [16]

*Treatment decisions supported by the supplied evidence. [1][2][3][14][19][20]*

| Clinical situation | Decision-supported approach | Important qualification |
| --- | --- | --- |
| Moderate-to-severe uncomplicated luminal disease | Use systemic corticosteroids for induction. [1] | Consider early biologic therapy with extensive disease or poor prognostic features. [1] |
| Mild-to-moderate disease | Budesonide, sulfasalazine, and dietary modifications are described induction options. [14] | Location-specific selection and current guideline review are necessary; supplied sources do not provide dosing. [14] |
| Steroid-dependent or steroid-resistant disease | Use a steroid-sparing strategy; azathioprine or mercaptopurine and, when needed, methotrexate are described conventional options. [2] | Biologic therapy is appropriate after conventional-treatment failure, intolerance, or for moderate-to-severe disease. [19] |
| Consideration of 5-aminosalicylates | Do not routinely use 5-aminosalicylates for Crohn disease. [3] | The cited guideline also found no compelling role in postoperative maintenance. [3] |

## Monitor objectively and investigate discordance

Symptoms, biomarkers, endoscopy, and imaging answer different questions.

Assess patients in remission regularly with clinical review plus CRP and/or fecal calprotectin as adjunctive markers. [15] A rise in fecal calprotectin should prompt evaluation for inflammatory recurrence, but decisions should account for disease location, baseline biomarker behavior, and alternative causes of symptoms or marker elevation.

Endoscopy remains the reference standard for assessing mucosal activity and confirming mucosal healing, although it is invasive and costly. [16] Fecal calprotectin can reduce the need for repeated endoscopy in selected settings: in one study, a value of 250 micrograms/g or less predicted endoscopic remission defined as CDEIS 3 or less with sensitivity 94.1% and negative predictive value 96.6%, but specificity was 62.2% and positive predictive value 48.5%. [16] This threshold should not be treated as universally applicable.

After intestinal resection, fecal calprotectin measurement has a potentially valuable role in monitoring recurrence. [24] One monitoring strategy evaluates fecal calprotectin at 3 months after surgery and considers earlier endoscopy if it rises, followed by endoscopic assessment after the initial postoperative evaluation. [17]
- Escalate evaluation for biomarker elevation despite minimal symptoms rather than assuming remission. [16]
- Evaluate ongoing symptoms with normal inflammatory assessment for noninflammatory causes before changing immunosuppressive therapy. [22]
- Use endoscopy and other diagnostic modalities when phenotype or diagnosis may have changed; initial endoscopy plus biopsy does not permanently settle classification in every patient. [16]

*Clinical interpretation of common monitoring discordance. [15][16][22]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Symptoms improve but fecal calprotectin remains elevated | Clinical improvement may not reflect endoscopic remission. [16] | Reassess inflammatory burden with disease-location-appropriate objective testing. [16] |
| Symptoms persist but CRP is normal | Normal CRP does not exclude active Crohn disease in an individual patient. [22] | Use fecal biomarkers, endoscopy, or imaging according to phenotype and suspected location. [14][15] |
| Low fecal calprotectin in suspected isolated ileal disease | Fecal markers can have diminished value in small-bowel-restricted Crohn disease. [15][16] | Do not exclude active disease solely on the biomarker; consider cross-sectional imaging or other appropriate evaluation. [14][16] |

## Integrate surgery early when disease is localized or complications are not medically manageable

Surgery is a disease-management option, not only a last resort.

Consider surgery for localized disease and involve colorectal surgery promptly for life-threatening complications. Emergency surgery is indicated for intestinal perforation, refractory bleeding, or toxic megacolon; elective surgery is indicated for dysplasia or malignancy, refractory disease, or inability to tolerate long-term immunosuppression or other pharmacologic therapy. Laparoscopy is preferred when feasible. [2]

Perianal and fistulizing disease requires control of infection followed by advanced medical therapy. [14] The supplied evidence does not provide procedural sequencing, drainage technique, antibiotic regimens, or biologic dosing; these decisions should be coordinated with an experienced multidisciplinary IBD and colorectal surgery team.
- Suspect a structural or penetrating complication when symptoms are disproportionate, obstructive, systemic, or refractory to apparently appropriate anti-inflammatory therapy; obtain cross-sectional assessment as clinically indicated. [14]
- Use postoperative biomarker and endoscopic surveillance rather than symptom-based follow-up alone. [17][24]

*Surgical indications described in Crohn disease consensus evidence. [2]*

| Setting | Indication | Management implication |
| --- | --- | --- |
| Emergency | Perforation, refractory bleeding, or toxic megacolon. [2] | Urgent surgical evaluation and operative management. [2] |
| Elective | Dysplasia or malignancy, refractory course, or intolerance to long-term immunosuppression or other pharmacotherapy. [2] | Discuss surgery as a planned therapeutic alternative; use laparoscopy when feasible. [2] |
| Localized disease | Surgery should always be considered as an option. [2] | Balance resection against expected medical-treatment burden and disease phenotype. [2] |

## Address immunization, deficiencies, and colorectal cancer risk

Preventive care should be built into every treatment transition.

Document vaccination history at diagnosis and before immunomodulator or biologic therapy, then update vaccines as appropriate. Live vaccines should not be administered during immunosuppressive therapy; if feasible, give them at least 4 weeks before treatment initiation or at least 3 months after immunosuppression has stopped. [1]

Monitor and correct nutritional and hematinic deficits, including iron, vitamin D, folate, and vitamin B12. [14] For colorectal cancer surveillance, an evidence summary notes that most guidelines recommend colonoscopy beginning 8 years after symptom onset, with subsequent intervals determined by additional risk factors. [14] The supplied evidence does not specify risk-stratified U.S. surveillance intervals.
- Review preventive care before starting or changing immunosuppressive therapy rather than after treatment has begun. [1]
- Use disease extent and additional colorectal cancer risk factors to determine surveillance intensity after the initial 8-year time point. [14]

*Preventive-care actions supported by the supplied evidence. [1][14]*

| Action | When | Evidence-supported detail |
| --- | --- | --- |
| Vaccination review | At diagnosis and before immunomodulator or biologic therapy. [1] | Update vaccines; avoid live vaccines during immunosuppressive therapy. [1] |
| Deficiency assessment | Initial and ongoing care as clinically indicated. [14] | Assess iron, 25-hydroxyvitamin D, folate, and vitamin B12. [14] |
| Colorectal cancer surveillance | Approximately 8 years after symptom onset. [14] | Subsequent monitoring depends on additional risk factors. [14] |

## Common questions

### Can normal CRP exclude active Crohn disease?

No. CRP may not correlate with an individual patient's active disease or endoscopic status. Use fecal calprotectin, endoscopy, and/or cross-sectional imaging according to phenotype and suspected disease location. [15][16][22]

### When is capsule endoscopy useful in suspected Crohn disease?

Capsule endoscopy is an adjunct when there is a high index of suspicion for small-bowel Crohn disease. Deep enteroscopy is not routine but may be useful when small-bowel tissue sampling is needed for diagnosis. [2][18]

### Do 5-aminosalicylates have a role in Crohn disease?

The cited British Society of Gastroenterology guideline concludes that 5-aminosalicylates have little to no role in Crohn disease management and finds no compelling evidence for postoperative maintenance use. [3]

### When should surgery be discussed in Crohn disease?

Discuss surgery for localized disease and for elective indications such as dysplasia or malignancy, refractory disease, or intolerance to long-term immunosuppression. Perforation, refractory bleeding, and toxic megacolon require emergency surgical management. [2]

## References
1. British Society of Gastroenterology consensus guidelines ... — gut.bmj.com — https://gut.bmj.com/content/68/Suppl_3/s1
2. Core indicators of an evaluation and guidance system for quality of care in inflammatory bowel disease centers: A critical review — www.thelancet.com — https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00112-2/fulltext
3. British Society of Gastroenterology guidelines on ... — gut.bmj.com — https://gut.bmj.com/content/74/Suppl_2/s1
4. Inflammatory bowel disease: recent developments — adc.bmj.com — https://adc.bmj.com/content/archdischild/early/2023/07/19/archdischild-2023-325668.full.pdf
5. Rise of precision medicine: can it deliver on its promise in ... — gut.bmj.com — https://gut.bmj.com/content/75/1/176
6. Chronic pouchitis: what every gastroenterologist needs to ... — fg.bmj.com — https://fg.bmj.com/content/16/2/143
7. Supplementary appendix — www.thelancet.com — https://www.thelancet.com/cms/10.1016/S2468-1253(23)00193-0/attachment/f413b70e-7d55-4d3b-97b2-9d97d36b61ed/mmc1.pdf
8. The cost of inflammatory bowel disease in high-income ... — www.thelancet.com — https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00003-1/abstract
9. De-escalation of immunomodulator and biological therapy ... — www.thelancet.com — https://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30186-4/abstract
10. Using clinical factors to predict treatment outcomes and ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2210740126001154
11. Core indicators of an evaluation and guidance system for ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2589537022001122
12. Definitions, diagnosis, management, and outcomes of ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2468125325003474
13. AGA Medical Position Statement on the Diagnosis and ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0016508509022021
14. Crohn's Disease: Diagnosis and Management : American Family Physician — journals.lww.com — https://journals.lww.com/00000405-202608000-00012
15. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management | Journal of Crohn's and Colitis | Oxford Academic — academic.oup.com — https://academic.oup.com/ecco-jcc/article/11/1/3/2456546
16. European evidence based consensus for endoscopy in inflammatory bowel disease | Journal of Crohn's and Colitis | Oxford Academic — academic.oup.com — https://academic.oup.com/ecco-jcc/article/7/12/982/446087
17. Optimising monitoring in the management of Crohn's disease — academic.oup.com — https://academic.oup.com/ecco-jcc/article/7/8/653/499880
18. Definitions and diagnosis | Journal of Crohn's and Colitis — academic.oup.com — https://academic.oup.com/ecco-jcc/article/4/1/7/402141
19. Treatment Pathways Leading to Biologic Therapies... : Clinical and Translational Gastroenterology — journals.lww.com — https://journals.lww.com/ctg/fulltext/2020/02000/treatment_pathways_leading_to_biologic_therapies.4.aspx
20. Systematic Review and Meta-analysis : Inflammatory Bowel Diseases — journals.lww.com — https://journals.lww.com/00054725-201708000-00009
21. Update in Medical Treatment of Crohn's Disease — journals.lww.com — https://journals.lww.com/jcge/fulltext/2000/12000/update_in_medical_treatment_of_crohn_s_disease.4.aspx
22. Crohn's Overview of Comments — www.ema.europa.eu — https://www.ema.europa.eu/en/documents/other/overview-comments-received-draft-guideline-development-new-medicinal-products-treatment-crohns-disease_en.pdf
23. Biomarkers of Inflammation in Inflammatory Bowel Disease — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085%2815%2900938-5/fulltext
24. Measurement of Fecal Calprotectin Improves Monitoring ... — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(15)00111-0/fulltext

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.